tagraxofusp-erzs + pomalidomide + dexamethasone

**Tagraxofusp-erzs** is a targeted fusion protein composed of interleukin-3 (IL-3) fused to truncated diphtheria toxin, acting as a CD123-directed cytotoxin that binds to CD123-expressing cells (notably in blastic plasmacytoid dendritic cell neoplasm and other hematologic malignancies) and causes cell death via inhibition of protein synthesis. **Pomalidomide** is an immunomodulatory small molecule that enhances T-cell and NK cell immune response, inhibits angiogenesis, and disrupts microenvironment support for malignant cells. **Dexamethasone** is a potent synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects, often used in combination with other agents in hematologic cancers. This combination is experimental with no published clinical evidence as a defined regimen; each drug is approved in specific hematologic malignancies but not together as a set.

Other names

tagraxofusptagraxofusp-erzspomalidomideCC4047CC-4047CC 4047dexamethasone